← GIP/GLP-1 & amylin agonists × adverse events & safety

SynthesisInternational journal of obesity (2005)2023

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.

Yasmin Luz Lima de Mesquita et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 4,036 people · 2023

Randomised comparison

Lowered body weight & composition

−8.10percentage points−11.0 to −5.20

As reported

difference −8.1 %, 95% CI −11.0 to −5.20

Randomised comparison

Raised adverse events & safety

4.2×2.4× to 7.5×

Bigger than 9 in 10 for adverse events & safety

As reported

OR 4.2, 95% CI 2.40–7.50

Randomised comparison

Raised adverse events & safety

7×4.3× to 11×

Bigger than almost all for adverse events & safety

As reported

OR 7.0, 95% CI 4.30–11.4

Randomised comparison

Raised adverse events & safety

2.8×1.6× to 4.9×

Bigger than 9 in 10 for adverse events & safety

As reported

OR 2.8, 95% CI 1.60–4.90

Four numbers in the abstract

the abstract, start to end

… and MD in percent change in weight of -8.1% (95% CI -11.0, -5.2; …

… tirzepatide with respect to nausea (OR 4.2; 95% CI 2.4, 7.5; p < 0.001), vomiting (OR 7.0; 95% CI 4.3, 11.4; p < 0.001), and diarrhea (OR 2.8; 95% CI 1.6, 4.9; p < 0.001) …

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−8.1−11.0 to −5.20
Adverse events & safety
OR 4.22.40–7.50
Adverse events & safety
OR 7.04.30–11.4
Adverse events & safety
OR 2.81.60–4.90
GIP/GLP-1 & amylin agonistsBody weight & compositionAdverse events & safety

GIP/GLP-1 & amylin agonists × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

27 papers cite it

2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 37460681